Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-08-14
1999-02-09
Schenkman, Leonard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514220, 5142262, 514255, 514264, 514290, 514296, 514322, 514324, 514326, 514343, 514352, 514357, 514397, 514400, 514849, A61K 3144, A61K 3155
Patent
active
058694790
ABSTRACT:
Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H.sub.1 receptor antagonist; together with (b) a sufficient amount of a histamine H.sub.3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or separately in the same or different dosage forms to maintain therapeutic systemic levels of both components.
REFERENCES:
patent: 2567245 (1951-09-01), Sperber et al.
patent: 4282233 (1981-08-01), Vilani
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5217986 (1993-06-01), Pomponi et al.
patent: 5352707 (1994-10-01), Pomponi et al.
R.W.S. Hew et al., "Characterization of Histamine H.sub.3 -Receptors in Guinea-Pig Ileum with H.sub.3 -Selective Ligands," British Journal of Pharmacology, vol. 101, pp. 621-624 (1990).
C.E. Tedford et al., "Pharmacological Characterization of GT-2016, A Non-Thiourea-Containing Histamine H.sub.3 Receptor Antagonist: In Vitro and In Vivo Studies," The Journal of Pharmacology and Experimental Therapeutics, vol. 275, pp. 598-604 (1995).
J.W. Clitherow et al., "Novel 1,24-Oxadiazoles as Potent and Selective Histamine H.sub.3 Receptor Antagonists," Bioorganic and Medicinal Chemistry Letters, vol. 6, pp. 833-838 (1996).
C.R. Ganellin et al., "Design of Potent Non-Thiourea H.sub.3 Receptor Histamine Antagonists," Journal of Medicinal Chemistry, vol. 38, pp. 3342-3350 (1995).
M. Misawa et al., "Pharmacological Studies on the Respiratory Tract (Rept. 186): The Effects of Histamine Receptor Antagonists on Guinea Pig Rhinitis Model," Japanese Journal of Pharmacology, vol. 64, No. S1, Abstract P-246 (1994).
C.J. Matson et al., "An Experimental Non-Invasive Animal Technique for Measuring Nasal Airway Resistance: I. Adrenergic and Antihistaminic Agents," Archives Internationales de Pharmacodynamie et de Therapie, vol. 232, pp. 68-78 (1978).
N. Sakai et al., "Effects of Thioperamide, a Histamine H.sub.3 Receptor Antagonist, on Locomotor Activity and Brain Histamine Content in Mast Cell-Deficient W/W.sup.v Mice," Life Sciences, vol. 48, pp. 2397-2404 (1991).
F.E.R. Simons, "H.sub.1 -Receptor Antagonists: Clinical Pharmacology and Therapeutics," Journal of Allergy and Clinical Immunology, vol. 84, pp. 845-861 (1989).
A. Korte et al., "Characterization and Tissue Distribution of H.sub.3 Histamine Receptors in Guinea Pigs by N.sup..alpha. -Methylhistamine,"Biochemical and Biophysical Research Communications, vol. 168, pp. 979-986 (1990).
Hey John A.
Kreutner William
Franks Robert A.
Schenkman Leonard
Schering Corporation
LandOfFree
Treatment of upper airway allergic responses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of upper airway allergic responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of upper airway allergic responses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1948572